Life Planning Partners Inc Has $51,000 Holdings in AbbVie Inc. (NYSE:ABBV)

Life Planning Partners Inc lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 17,670.0% in the 4th quarter, Holdings Channel reports. The firm owned 284,853 shares of the company’s stock after buying an additional 283,250 shares during the quarter. Life Planning Partners Inc’s holdings in AbbVie were worth $51,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ABBV. G&S Capital LLC lifted its position in AbbVie by 267.8% during the 4th quarter. G&S Capital LLC now owns 21,268 shares of the company’s stock worth $3,779,000 after acquiring an additional 15,485 shares during the last quarter. Avestar Capital LLC lifted its position in AbbVie by 12.3% during the 4th quarter. Avestar Capital LLC now owns 12,866 shares of the company’s stock worth $2,286,000 after acquiring an additional 1,413 shares during the last quarter. MGB Wealth Management LLC lifted its position in AbbVie by 3.8% during the 4th quarter. MGB Wealth Management LLC now owns 13,638 shares of the company’s stock worth $2,416,000 after acquiring an additional 493 shares during the last quarter. Morris Financial Concepts Inc. lifted its position in AbbVie by 7.0% during the 4th quarter. Morris Financial Concepts Inc. now owns 2,736 shares of the company’s stock worth $486,000 after acquiring an additional 179 shares during the last quarter. Finally, Hemington Wealth Management lifted its position in AbbVie by 6.3% during the 4th quarter. Hemington Wealth Management now owns 2,536 shares of the company’s stock worth $450,000 after acquiring an additional 150 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the transaction, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This represents a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.25% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Daiwa Capital Markets lowered shares of AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 target price for the company. in a research report on Thursday, December 5th. Morgan Stanley upped their price objective on shares of AbbVie from $224.00 to $239.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Bank of America reaffirmed a “neutral” rating and set a $191.00 price objective on shares of AbbVie in a research report on Tuesday, December 10th. JPMorgan Chase & Co. cut their price objective on shares of AbbVie from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. Finally, Wells Fargo & Company upped their price objective on shares of AbbVie from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $208.35.

AbbVie Price Performance

Shares of AbbVie stock opened at $193.00 on Friday. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64. The stock has a market capitalization of $341.05 billion, a price-to-earnings ratio of 80.42, a P/E/G ratio of 1.53 and a beta of 0.58. AbbVie Inc. has a 1-year low of $153.58 and a 1-year high of $207.32. The firm’s 50-day moving average price is $178.59 and its two-hundred day moving average price is $185.96.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same quarter last year, the business earned $2.79 EPS. On average, equities analysts predict that AbbVie Inc. will post 12.32 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.40%. AbbVie’s payout ratio is 273.33%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.